Rate My Professor Golo Ahlenstiel

Professor Golo Ahlenstiel, MD/PhD, FRACP, is a clinician-scientist and hepatologist specializing in liver immunology and chronic liver disease. He completed his medical degree and PhD at the University of Bonn in Germany, followed by a Liver Fellowship at the U.S. National Institutes of Health in 2004 with fellowships from the NIH and the German Research Foundation. Ahlenstiel relocated to Australia in 2009, completing advanced training in Gastroenterology and Hepatology within the Western Sydney Local Health District by 2013. In 2014, he was appointed Associate Professor at the University of Sydney and staff specialist in Gastroenterology and Hepatology at Westmead Hospital. Since 2017, he has served as Chair of Medicine at Blacktown Clinical School, School of Medicine, Western Sydney University, and Head of Gastroenterology & Hepatology at Blacktown-Mount Druitt Hospital. He also acts as Clinical Network Director for Specialty Medicine in Western Sydney Local Health District and leads the Liver Immunology Group at the Storr Liver Centre, Westmead Institute for Medical Research. His clinical practice covers the full spectrum of gastroenterology and hepatology with a focus on patient-centered care.

Ahlenstiel's research encompasses innate immunity, viral hepatitis, metabolic liver disease, liver cirrhosis, portal hypertension, and the immunology of liver cancer, including the epidemiology of orphaned liver diseases and phage translocation in systemic inflammation. His scholarship includes 146 articles, chapters, and other outputs, amassing over 7,000 career citations. Prominent publications are “IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy” (Nature Genetics, 2009), “The role of zinc in antiviral immunity” (Advances in Nutrition, 2019), “Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa–dependent manner” (Gastroenterology, 2010), “Global multi-stakeholder endorsement of the MAFLD definition” (The Lancet Gastroenterology & Hepatology, 2022), and “Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C” (Gut, 2006). He has received the Fellow GESA (2022), WSLHD Award for Collaborative Leadership (2022), NSW Public Servant of the Year Finalist (2022), and Westmead Institute Scientific Excellence Awards (2018, 2016). Ahlenstiel contributes to the GESA Liver Faculty Executive and SPHERE TRIPLE III Executive, driving translational programs in liver disease and cancer immunotherapy.